Zacks.com on MSN2d
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & MorePipeline and regulatory updates are in focus in the biotech sector. Among these, BridgeBio Pharma, Inc. BBIO gained on ...
3d
Intech Investment Management LLC acquired a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) in the 3rd ...
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price upped by HC Wainwright from $43.00 to $49.00 in a research ...
Equities research analysts at Leerink Partnrs cut their FY2027 EPS estimates for shares of BridgeBio Pharma in a research ...
Research analysts at HC Wainwright increased their FY2024 earnings estimates for shares of BridgeBio Pharma in a research ...
The approval was based on positive results observed in the ATTRibute-CM Phase 3 study, where Attruby demonstrated a ...
Massachusetts Financial Services Co. MA lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 23.3% in ...
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price raised by Scotiabank from $45.00 to $48.00 in a report issued on Monday morning,Benzinga reports. The brokerage currently has a sector ...
With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry giant. The next-generation, oral, ...
In a report released today, Cory Kasimov from Evercore ISI reiterated a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price ...
In a report released on November 23, Joshua Schimmer from Cantor Fitzgerald maintained a Buy rating on BridgeBio Pharma (BBIO – Research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback